Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q3 2019 · 10-Q
Revenue$695.00K$695.00K−26.4% vs Q3 2018 Net Income-$11.23M-$11.23MN/M vs Q3 2018 EPS Diluted-$0.36-$0.36N/M vs Q3 2018 Operating Income-$11,230,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$9,282,000N/M Margins · derivedOperating margin-1615.8%−646.4 pt vs Q3 2018
Net margin-1615.8%−661.3 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 8, 2019 · 39 d after period end